ERNEST HAWK to Biomarkers, Tumor
This is a "connection" page, showing publications ERNEST HAWK has written about Biomarkers, Tumor.
Connection Strength
0.678
-
Multicancer early detection test: Preclinical, translational, and clinical evidence-generation plan and provocative questions. Cancer. 2022 02 15; 128 Suppl 4:861-874.
Score: 0.219
-
Urinary PGE-M in colorectal cancer: predicting more than risk? Cancer Prev Res (Phila). 2014 Oct; 7(10):969-72.
Score: 0.130
-
Biomarkers as surrogates for cancer development. Curr Oncol Rep. 2000 May; 2(3):242-50.
Score: 0.048
-
Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Ann Oncol. 2018 10 01; 29(10):2061-2067.
Score: 0.043
-
Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog. 2013 Nov; 52 Suppl 1:E139-47.
Score: 0.030
-
Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst. 2012 Oct 17; 104(20):1599-611.
Score: 0.029
-
Intake of red meat and heterocyclic amines, metabolic pathway genes and bladder cancer risk. Int J Cancer. 2012 Oct 15; 131(8):1892-903.
Score: 0.027
-
Translational Research Working Group developmental pathway for biospecimen-based assessment modalities. Clin Cancer Res. 2008 Sep 15; 14(18):5672-7.
Score: 0.022
-
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006 Jun 15; 12(12):3661-97.
Score: 0.018
-
Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev. 2003 Jul; 12(7):593-6.
Score: 0.015
-
Epidemiology and prevention of colorectal cancer. Surg Clin North Am. 2002 Oct; 82(5):905-41.
Score: 0.014
-
Circulating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics. Cancer Epidemiol Biomarkers Prev. 2021 09; 30(9):1643-1651.
Score: 0.013
-
Primary cancer prevention trials. Hematol Oncol Clin North Am. 2000 Aug; 14(4):809-30.
Score: 0.012
-
Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2000 Feb; 9(2):127-37.
Score: 0.012
-
Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem Suppl. 1996; 25:1-14.
Score: 0.009
-
Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. J Cell Biochem Suppl. 1995; 23:1-9.
Score: 0.008
-
Strategy for prevention of cancers of the esophagus. Ann N Y Acad Sci. 2014 Sep; 1325:108-26.
Score: 0.008
-
Cancer epidemiology, biomarkers & prevention, and cancer prevention research: two journals, a common goal. Cancer Epidemiol Biomarkers Prev. 2008 Nov; 17(11):2903-5.
Score: 0.005
-
Cancer prevention and the American Society of Clinical Oncology. J Clin Oncol. 2004 Oct 01; 22(19):3848-51.
Score: 0.004
-
Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol. 1999; 470:45-53.
Score: 0.003
-
Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring. Clin Chem. 1998 Feb; 44(2):420-7.
Score: 0.003
-
Perspectives and progress in development of breast cancer chemopreventive drugs. Prog Clin Biol Res. 1997; 396:159-83.
Score: 0.002
-
Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology (Williston Park). 1996 Oct; 10(10):1471-84; discussion 1484-8.
Score: 0.002